A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Inclusion Criteria:

- Men >=30 years of age with non-metastatic prostate cancer

- Have undergone bilateral orchiectomy or initiated ADT with GnRH agonists and is
expected to continue on ADT for at least 12 months

- ECOG score (0,1 or 2)

- Baseline BCVA of 20/40, (6/12 or 0.5 on the decimal scale) or better using the ETDRS
charts at 4 meters in one eye with a natural, intact lens

- Bone Mineral Density (BMD) requirements:

If <70 years: BMD T-score at the lumbar spine, total hip, or femoral neck >= -2.5 and
<=-1.0 (osteopenia) If >= 70 years of age: BMD T-score at lumbar spine and total hip and
femoral neck >= -2.5 At least 2 evaluable lumbar vertebrae

Exclusion Criteria:

- Screening LOCS III grade of >=3.5 for posterior subcapsular cataract, >= 4.0 for
cortical cataract, or >= 4.5 for nuclear opalescence

- Bone Mineral Density (BMD) T-score< -2.5 at lumbar spine and/or total hip and/or
femoral neck ("osteoporosis")

- evidence of distant metastases

- Known osteonecrosis of the jaw (ONJ)

- Unstable system disease including active infection, uncontrolled hypertension,
unstable angina, congestive heart failure, or myocardial infarction within 6 months
before randomization

- Incisional eye surgery in both eyes or cataract surgery in both eyes

- Current administration of IV bisphosphonates

- PSA > 5ng/mL at screening.